News

Press Releases
Nocion Therapeutics Announces First Patient Dosed in ASPIRE Phase 2b Chronic Cough Study
November 18, 2024 PDF VERSION
Nocion Therapeutics Presents Data on Preclinical and Clinical Development of Taplucainium, a Novel, Charged Sodium Channel Blocker, as a potential treatment for Chronic Cough at the 13th London International Cough Symposium
July 15, 2024 PDF VERSION
Nocion Therapeutics Appoints Dr. Catherine Bonuccelli to Scientific Advisory Board and Joan Shaw to Senior Vice President, Clinical Operations
July 8, 2024 PDF VERSION
Lumira Ventures Announces Investment in Nocion Therapeutics to Revolutionize Chronic Cough Treatment
April 2, 2024 PDF VERSION
Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Developmen
March 4, 2024 PDF VERSION
Nocion Therapeutics Announces Dosing Underway in Participants with Chronic Cough
August 31, 2021 PDF VERSION
Nocion Therapeutics Advances to Clinical Stage and Expands Leadership.
September 1, 2020 PDF VERSION
Nocion Therapeutics identifies lead clinical candidate for refractory chronic cough and expands the management team
NOVEMBER 18, 2019 PDF VERSION
FierceBiotech names Nocion Therapeutics as one of its “Fierce 15” Biotech Companies of 2019
SEPTEMBER 23, 2019 PDF VERSION
Nocion Therapeutics launches to selectively silence pain and itch neurons
APRIL 17, 2019 PDF VERSION

News Coverage
March 4, 2024 by Endpoints
March 4, 2024 by Boston Business Journal
August 26, 2021 by The University of Manchester
July 16, 2020 by Fierce Biotech
September 23, 2019 by Fierce Biotech